CORPORATE OVERVIEW

Zero Candida Technologies, Inc. (TSXV : ZCT) is revolutionizing women’s health, starting with transforming the treatment of Vulvo-Vaginal Candidiasis (“VVC”) – commonly known as yeast infections. Affecting approximately 75% of women globally, VVC is increasingly drug-resistant, with 10% of cases being recurrent (4+ episodes per year), as current treatments fail to address the root cause effectively.

ZCT’s groundbreaking technology, recognized by medical experts worldwide, has demonstrated what 99.999% success in preclinical tests in treating Candida fungus. Unlike traditional treatments, ZCT’s device is free from chemicals, side effects, frequent prescriptions, or the need for repeated doctor visits. By leveraging artificial intelligence, the device can collect and transmit real-time data directly to physicians for personalized consulting and treatment. 

Through partnerships with leading hospitals and a growing global patent portfolio, including full protection in South Africa, ZCT is committed to bringing gynecology into the 21st century through hybrid medicine and improving access for underserved populations.